Craig-Hallum raised the firm’s price target on Champions Oncology (CSBR) to $8 from $6 and keeps a Buy rating on the shares. The firm notes Champions’ Q2 results were very strong as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback